Background:LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance. Methods: First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promoter reporter constructs was determined in BeWo trophoblast-like cells with luciferase assays. Adjusted odds ratio (OR) was calculated for the A/A genotype combined with maternal risk factors. Results: The A/A, A/C, and C/C genotypes in the -98 promoter position were in Hardy-Weinberg equilibrium in the control but not in the PE group (p < 0.036). The dominant A/A genotype had higher frequency in the PE group (p < 0.001). The A/C and C/C genotypes protected from PE (p < 0.032). The ORs to develop term and all PE, calculated for the A/A genotype, previous PE, body mass index (BMI) >35, black ethnicity, and maternal age >40 were 15.6 and 11.0, respectively (p < 0.001). In luciferase assays, the “-98A” promoter variant had lower expression than the “-98C” variant in non-differentiated (-13%, p = 0.04) and differentiated (-26%, p < 0.001) BeWo cells. Forskolin-induced differentiation led to a larger expression increase in the “-98C” variant than in the “-98A” variant (4.55-fold vs. 3.85-fold, p < 0.001). Conclusion: Lower LGALS13 (PP13) expression with the “A” nucleotide in the -98 promoter region position (compared to “C”) and high OR calculated for the A/A genotype in the -98A/C promoter region position, history of previous PE, BMI >35, advanced maternal age >40, and black ethnicity could serve to aid in PE prediction in the first trimester.

Keywords:
Pregnancy disorders, Placenta, PCR, Gene expression, Galectins, Single nucleotide polymorphism, LGALS13, Preeclampsia
1.
Walker JJ: Pre-eclampsia. Lancet 2000;356:1260-1265.
2.
Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53-56.
3.
Khan KS, Wojdyla D, Say L, Metin-Gülmezoglu AM, Van Look PA: WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066-1074.
4.
Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-137.
5.
Redman CW, Sacks GP, Sargent IL: Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180(Pt 1):499-506.
6.
Nakimuli A, Chazara O, Byamugisha J, Elliott AM, Kaleebu P, Mirembe F, et al: Pregnancy, parturition and preeclampsia in women of African ancestry. Am J Obstet Gynecol 2013;210:510-20.e1.
7.
Pattinson R (ed); National Committee for the Confidential Enquiry into Maternal Deaths: Saving Mothers 2011-2013: Sixth Report on the Confidential Enquiries into Maternal Deaths in South Africa. Department of Health, South Africa, 2015, pp 1-93. http://www.kznhealth.gov.za/mcwh/Maternal/Saving-Mothers-2011-2013-short-report.pdf.
8.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
9.
Yang J, Shang J, Zhang S, Li H, Huiong L: The role of the rennin-angiotensin-aldosterone system in preeclampsia: genetic polymorphism and micro RNA. J Mol Endocrinol 2013;50:R53-R66.
10.
Yu CK, Casas JP, Savvidou MD, Sahemey MK, Nicolaides KH, Hingorani AD: Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysis. BMC Pregnancy Childbirth 2006; 16:1-9.
11.
Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, et al: Vascular endothelial growth factor gene polymorphism and pre-eclampsia. Mol Hum Reprod 2004;10:321-324.
12.
Chen P, Gong Y, Pu Y, Wang Y, Zhou B, Song Y, et al: Association between polymorphisms in IL-27 gene and pre-eclampsia. Placenta 2016;37:61-64.
13.
Arias F, Rodriquez L, Rayne SC, Kraus FT: Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynecol 1993;168:585-591.
14.
Gebhardt S, Bruiners N, Hillerman R: A novel exonic variant (221DelT) in the LGALS13 gene encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population. J Reprod Immunol 2009;82:166-173.
15.
Huppertz B: Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008;51:970-975.
16.
Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al: A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA 2009;16:9731-9736.
17.
Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al: A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
18.
Thilaganathan B: Placental syndromes: getting to the heart of the matter. Ultrasound Obstet Gynecol 2017;49:7-9.
19.
Osol G, Bernstein I: Preeclampsia and maternal cardiovascular disease: consequence or predisposition? J Vasc Res 2014;51:290-304.
20.
Than NG, Sumegi B, Than GN, Berente Z, Bohn H: Isolation and, sequence analysis of a cDNA encoding human placental tissue protein 13 (PP-13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. Placenta 1999;20:703-710.
21.
Balogh A, Pozsgay J, Matkó J, Dong Z, Kim CJ, Várkonyi T, et al: Placental protein 13 (PP13/Galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol 2011;205:156.e1-e14.
22.
Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M: Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum Reprod Update 2013;19:391-405.
23.
Kliman HJ, Sammar M, Grimpel Y-I, Lynch SK, Milano KM, Pick E, et al: Placental Protein 13 and decidual zones of necrosis: an immunologic diversion that may be linked to preeclampsia. Reprod Sci 2012;19:16-30.
24.
Than NG, Romero R, Balogh A, Karpati E, Mastrolia SA, Staretz-Chacham O, et al: Galectins: double edged swords in the cross-roads of pregnancy complications and female reproductive tract inflammation and neoplasia. J Pathol Transl Med 2015;49:181-208.
25.
Gizurarson S, Sigurdardottir ER, Meiri H, Huppertz B, Sammar M, Sharabi-Nov A, et al: Placental Protein 13 administration to pregnant rats lowers blood pressure and augments fetal growth and venous remodeling. Fetal Diagn Ther 2016;39:56-63.
26.
Sammar M, Nisemblat S, Fleischfarb Z, Golan A, Sadan O, Meiri H, et al: Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta 2011;32(suppl):S30-S36.
27.
Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, et al: Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol 2010;203:e1-e6.
28.
Bruiners N, Bosman M, Postma A, Gebhardt S, Rebello G, Sammar M, et al: Promoter variant -98A-C of the LGALS13 gene and pre-eclampsia. 8th World Congr Prenat Med Fetal Dev, Florence, September 2008.
29.
Hadlock FP, Shah YP, Kanon DJ, Lindsey JV: Fetal crown-rump length: re-evaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. Radiology 1992;182:501-505.
30.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH: Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010;30:216-223.
31.
Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH: Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:583-586.
32.
Poon LCY, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH: Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34:142-148.
33.
Lindheimer MD, Taler SJ, Cunningham FG: American Society of Hypertension position paper: hypertension in pregnancy. Clin Hypertens (Greenwich) 2009;11:214-225.
34.
Than NG, Romero R, Xu Y, Erez O, Xu Z, Bhatti G, et al: Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. Placenta 2014;35:855-865.
35.
Long CA, Bauer GS, Lowe ME, Strauss AW, Gast MJ: Isolation and characterization of the gene from a human genome encoding 17β- estradiol dehydrogenase: a comparison of Jar and BeWo choriocarcinoma cell lines. Am J Obstet Gynecol 2010;163:1976-1981.
36.
Than NG, Balogh A, Romero R, Karpati E, Erez O, Szilagyi A, et al: Placental Protein 13 (PP13) - a placental immunoregulatory galectin protecting pregnancy. Front Immunol 2014;5:1-25.
37.
Sammar M, Nisamblatt S, Gonen R, Huppertz B, Gizurarson S, Osol G, et al: The role of the carbohydrate recognition domain of placental protein 13 (PP13) in pregnancy evaluated with recombinant PP13 and the DelT221 PP13 variant. PLoS One 2014;9:e102832.
38.
Hahn S. Preeclampsia - will orphan drug status facilitate innovative biological therapies? Front Surg 2015;2:1-4.
39.
Bogacz A, Bartkowiak-Wieczorek J, Procyk D, Seremak-Mrozikiewicz A, Majchrzycki M, Dziekan K, et al: Analysis of the gene polymorphism of aldosterone synthase (CYP11B2) and atrial natriuretic peptide (ANP) in women with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2016;197:11-15.
40.
Saidi S, Mahjoub T, Almawi WY: Aldosterone synthase gene (CYP11B2) promoter polymorphism as a risk factor for ischaemic stroke on Tunisian Arabs. J Renin Angiotensin Aldosteron Syst 2010;11:180-186.
41.
Lo HM, Lin FY, Lin JL, Tseng CD, Hsu KL, Chiang FT, et al: Electrophysiological properties in patients undergoing atrial compartment operation for chronic atrial fibrillation with mitral valve disease. Eur Heart J 1997;18:1805-1815.
42.
Ardizzone N, Cappello F, Di Felice V, Rappa F, Minervini F, Marasà S, et al: Atrial natriuretic peptide and CD34 overexpression in human idiopathic dilated cardiomyopathies. APMIS 2007;115:1227-1233.
43.
Lade JA, Moses EK, Guo G, Wilton AN, Grehan M, Cooper DW, et al: The eNOS gene: a candidate for the preeclampsia susceptibility locus? Hypertens Pregnancy 1999;18:81-93.
44.
Pridjian G, Puschett JB: Preeclampsia. 2. Experimental and genetic considerations. Obstet Gynecol Surv 2002;57:619-640.
45.
Smith GC, Pell JP, Walsh D: Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002-2006.
46.
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, et al: Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison to NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol, DOI 10.1002/uog.17455.
47.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016;214:103.e1-103.e12.
48.
Rolnik D, Wright D, Poon LC, O'Gorman N, Syngelaki A: Aspirin versus placebo in pregnancies at high risk of preterm preeclampsia, submitted.
49.
Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, et al: Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med 2016;374:434-443.
50.
Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R: Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001;98(Pt 1):757-762.
51.
Than NG, Romero R, Meiri H, Erez O, Xu Y, et al: PP13, maternal ABO blood groups and the risk assessment of pregnancy complications. PLoS One 2011;6:e21564.
52.
Drobnjak T, Gizurarson S, Gokina NI, et al: Placental protein 13 (PP13)-induced vasodilation of resistance arteries from pregnant and nonpregnant rats occurs via endothelial signaling pathways. Pregnancy Hypertens, in press.
53.
Lo YMD, Chan KCA, Dun H, Chen EZ, Jiang P, Lun FMF, Zheng YW, Leung TY, Lau TK, Cantor CR, Chiu RWK: Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010;2:61ra91.
54.
Rigourd V, Chelbi S, Chauvet C, Rebourcet R, Barbaux S, Bessières B, et al: Re-evaluation of the role of STOX1 transcription factor in placental development and preeclampsia. J Reprod Immunol 2009;82:174-181.
55.
Fong FM, Sahemey MK, Hamedi G, Eyitayo R, Yates D, Kuan V, et al: Maternal genotype and severe preeclampsia: a HuGE review. Am J Epidemiol 2014;180:335-345.
56.
Haram K, Mortensen JH, Nagy B: Genetic aspects of preeclampsia and the HELLP syndrome. J Pregnancy 2015;2014:1-13.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.